All In Biotech

Free tool

FAERS Monitor: Vemlidy

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 208464 or its brand name (Vemlidy, Tenofovir Alafenamide Fumarate). Reports on generic versions are filed under their own applications.

Reports

4,168

Serious

2,952

71% of reports

Hospitalization

1,184

Death reported

436

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • death254
  • product dose omission issue184
  • off label use172
  • fatigue144
  • drug ineffective125
  • diarrhoea96
  • headache92
  • nausea92
  • drug interaction89
  • product use issue88
  • neoplasm malignant72
  • rash72
  • hepatitis b71
  • product dose omission71
  • intentional dose omission69

Reports by year received

View as table
YearReports
20151
20163
2017108
2018310
2019513
2020413
2021536
2022551
2023510
2024473
2025419
2026331

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,049,991 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
hepatitis bSignal7160.247.74,024
intentional dose omissionSignal6912.29.7700
product dose omissionSignal715.54.4257
neoplasm malignantSignal725.44.3258
product dose omission issueSignal1843.22.7273
drug interactionSignal892.82.3104
product use issueSignal882.41.968
death2541.51.342
off label use1721.00.90
fatigue1440.90.81
rash720.80.72
diarrhoea960.80.68
headache920.70.68
nausea920.60.527
drug ineffective1250.50.475

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.